Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma - a study based on Pan-Cancer Analysis

Sep 24, 2026

Upload by Eliana

Nonerythrocytic spectrin beta 1 (SPTBN1) is a cytoskeletal protein implicated in normal cell growth through TGFβ/Smad signaling and is aberrantly expressed across cancers, yet its pan-cancer role remains unclear. This study analyzes SPTBN1 expression patterns and prognostic landscapes across human tumors, then evaluates prognostic/therapeutic potential and immune-related functions in kidney renal clear cell carcinoma (KIRC) and uveal melanoma (UVM). Using multiple databases, R packages, TIMER 2.0, and validation in patient cohorts and GEO, the work links SPTBN1 to cancer survival and tumor immunity.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages20

Reading Time50 min

AccessFree to download

Abstract

Background

Methods

Expression and survival analyses

Immune association analyses

Validation

Results

Conclusions

Keywords

Introduction

Tang et al. BMC Cancer (2023) 23:303 BMC Cancer [https://doi.org/10.1186/s12885-023-10789-3](https://doi.org/10.1186/s12885-023-10789-3) RESEARCH Open Access Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer Analysis Wenting Tang1,2†, Qiong Shao1,2†, Zhanwen He3,4†, Xu Zhang1,2, Xiaojuan Li3,5* and Ruohao Wu3,4* Abstract Background Nonerythrocytic spectrin beta 1 (SPTBN1) is an important cytoskeletal protein that involves in normal cell growth and development via regulating TGFβ/Smad signaling pathway, and is aberrantly expressed in various cancer types. But, the exact role of SPTBN1 in pan-cancer is still unclear. This report aimed to display expression patterns and prognostic landscapes of SPTBN1 in human cancers, and further assess its prognostic/therapeutic value and immunological role in kidney renal carcinoma (KIRC) and uveal melanoma (UVM) . Methods We firstly analyzed expression patterns and prognostic landscapes of SPTBN1 in human cancers using various databases and web-based tools. The relationships between SPTBN1 expression and survival/tumor immunity in KIRC and UVM were further investigated via R packages and TIMER 2.0 platform. The therapeutic roles of SPTBN1 in KIRC and UVM were also explored via R software. Following this, the prognostic value and cancer immunological role of SPTBN1 in KIRC and UVM were validated in our cancer patients and GEO database. Results Overall, cancer tissue had a lower expression level of SPTBN1 frequently in pan-cancer, compared with those in adjacent nontumor one. SPTBN1 expression often showed a different effect on survival in pan-cancer; upregulation of SPTBN1 was protective to the survival of KIRC individuals, which was contrary from what was found in UVM patients. In KIRC, there were significant negative associations between SPTBN1 expression and pro-tumor immune cell infiltration, including Treg cell, Th2 cell, monocyte and M2-macrophage, and expression of immune modulator genes, such as tumor necrosis factor superfamily member 9 (TNFSF9); while, in UVM, these correlations exhibited opposite patterns. The following survival and expression correlation analysis in our cancer cohorts and GEO database †Wenting Tang, Qiong Shao and Zhanwen He have contributed equally to this work. *Correspondence: Xiaojuan Li[lixj75@mail.sysu.edu.cn](lixj75@mail.sysu.edu.cn)[ ](lixj75@mail.sysu.edu.cn)Ruohao Wu [wurh6@mail.sysu.edu.cn](wurh6@mail.sysu.edu.cn) Full list of author information is available at the end of the article © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The)[. The](http://creativecommons.org/licenses/by/4.0/. The)[ ](http://creativecommons.org/licenses/by/4.0/. The)Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Tang et al. BMC Cancer (2023) 23:303 Page 2 of 20 confirmed these previ

FAQs

What is the biological role of SPTBN1 described in the study?

SPTBN1 is presented as an important cytoskeletal protein involved in normal cell growth and development, with links to TGFβ/Smad signaling, and aberrant expression across cancers.

How was SPTBN1 expression and prognosis assessed in KIRC and UVM?

The study uses public databases and web-based tools to evaluate expression patterns and prognostic landscapes, then examines survival and tumor immunity associations in KIRC and UVM using R packages and TIMER 2.0, with further validation in cancer patients and GEO datasets.

What key differences in SPTBN1 associations with survival and immunity were found between KIRC and UVM?

SPTBN1 expression correlated with survival differently across cancers: higher SPTBN1 was protective in KIRC but showed an opposite pattern in UVM. Immune associations also differed, with KIRC showing negative relationships between SPTBN1 and pro-tumor immune infiltration, while UVM displayed opposite correlations.

Sep 24, 2026

Upload by Eliana